{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-007291","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.476593+00:00","generated_at":"2026-06-22T02:20:29.421796+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Celldex reports Q3 2022 net loss of $26.8M; cash $323.5M; barzolvolimab data readouts planned","bullets":["Net loss per share ($0.57) in Q3 2022 vs ($0.45) in Q3 2021; nine-month net loss ($85.8M) includes $15M litigation settlement.","Revenue $0.4M in Q3, down from $0.2M in Q3 2021; R&D expenses rose to $21.6M on barzolvolimab trial and manufacturing.","Cash, cash equivalents and marketable securities $323.5M as of Sept 30, 2022; management says sufficient through 2025.","Phase 2 barzolvolimab studies in CSU, CIndU ongoing; 12-week data from Phase 1b CSU due Feb 2023; CIndU cohort data expected Dec 2022.","CDX-585 (ILT4 & PD-(L)1 bispecific) expected to enter clinic in 2023; CDX-527 (PD-L1 & CD27) discontinued due to evolving competitive landscape and internal hurdles."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-007291","json":"https://secwatch.observer/filing/0001171843-22-007291.json","markdown":"https://secwatch.observer/filing/0001171843-22-007291.md","text":"https://secwatch.observer/filing/0001171843-22-007291.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000117184322007291/0001171843-22-007291-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000117184322007291/f8k_110922.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:20:29.421796+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9c27f21286a6e8c74c72fa676f320de7209f308c","claim":"Celldex Therapeutics, Inc. reported financial results for third quarter of 2022.","evidence_excerpt":"On November 9, 2022, Celldex Therapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/744218/000117184322007291/0001171843-22-007291-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}